BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 29702695)

  • 1. Performance of next-generation sequencing on small tumor specimens and/or low tumor content samples using a commercially available platform.
    Morris SM; Subramanian J; Gel ES; Runger GC; Thompson EJ; Mallery DW; Weiss GJ
    PLoS One; 2018; 13(4):e0196556. PubMed ID: 29702695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using "residual" FNA rinse and body fluid specimens for next-generation sequencing: An institutional experience.
    Wei S; Lieberman D; Morrissette JJ; Baloch ZW; Roth DB; McGrath C
    Cancer Cytopathol; 2016 May; 124(5):324-9. PubMed ID: 26682952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors affecting the success of next-generation sequencing in cytology specimens.
    Roy-Chowdhuri S; Goswami RS; Chen H; Patel KP; Routbort MJ; Singh RR; Broaddus RR; Barkoh BA; Manekia J; Yao H; Medeiros LJ; Staerkel G; Luthra R; Stewart J
    Cancer Cytopathol; 2015 Nov; 123(11):659-68. PubMed ID: 26230354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Test Feasibility of Next-Generation Sequencing Assays in Clinical Mutation Detection of Small Biopsy and Fine Needle Aspiration Specimens.
    Zheng G; Tsai H; Tseng LH; Illei P; Gocke CD; Eshleman JR; Netto G; Lin MT
    Am J Clin Pathol; 2016 May; 145(5):696-702. PubMed ID: 27247373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Young investigator challenge: Can the Ion AmpliSeq Cancer Hotspot Panel v2 be used for next-generation sequencing of thyroid FNA samples?
    Bellevicine C; Sgariglia R; Malapelle U; Vigliar E; Nacchio M; Ciancia G; Eszlinger M; Paschke R; Troncone G
    Cancer Cytopathol; 2016 Nov; 124(11):776-784. PubMed ID: 27717198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilization of cytology smears improves success rates of RNA-based next-generation sequencing gene fusion assays for clinically relevant predictive biomarkers.
    Ramani NS; Chen H; Broaddus RR; Lazar AJ; Luthra R; Medeiros LJ; Patel KP; Rashid A; Routbort MJ; Stewart J; Tang Z; Bassett R; Manekia J; Barkoh BA; Dang H; Roy-Chowdhuri S
    Cancer Cytopathol; 2021 May; 129(5):374-382. PubMed ID: 33119213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies.
    Houghton J; Hadd AG; Zeigler R; Haynes BC; Latham GJ
    J Vis Exp; 2016 Apr; (110):e53836. PubMed ID: 27166994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens.
    Hadd AG; Houghton J; Choudhary A; Sah S; Chen L; Marko AC; Sanford T; Buddavarapu K; Krosting J; Garmire L; Wylie D; Shinde R; Beaudenon S; Alexander EK; Mambo E; Adai AT; Latham GJ
    J Mol Diagn; 2013 Mar; 15(2):234-47. PubMed ID: 23321017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical validation of the 50 gene AmpliSeq Cancer Panel V2 for use on a next generation sequencing platform using formalin fixed, paraffin embedded and fine needle aspiration tumour specimens.
    Rathi V; Wright G; Constantin D; Chang S; Pham H; Jones K; Palios A; Mclachlan SA; Conron M; McKelvie P; Williams R
    Pathology; 2017 Jan; 49(1):75-82. PubMed ID: 27913044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-generation sequencing of cytologic preparations: An analysis of quality metrics.
    Hwang DH; Garcia EP; Ducar MD; Cibas ES; Sholl LM
    Cancer Cytopathol; 2017 Oct; 125(10):786-794. PubMed ID: 28727266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporating cytologic adequacy assessment into precision oncology workflow using telepathology: An institutional experience.
    Al Zoughbi W; Kim D; Alperstein SA; Ohara K; Manohar J; Greco N; Khani F; Robinson BD; Rao RA; Elemento O; Mosquera JM; Siddiqui MT
    Cancer Cytopathol; 2021 Nov; 129(11):874-883. PubMed ID: 33929788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics.
    Kanagal-Shamanna R; Portier BP; Singh RR; Routbort MJ; Aldape KD; Handal BA; Rahimi H; Reddy NG; Barkoh BA; Mishra BM; Paladugu AV; Manekia JH; Kalhor N; Chowdhuri SR; Staerkel GA; Medeiros LJ; Luthra R; Patel KP
    Mod Pathol; 2014 Feb; 27(2):314-27. PubMed ID: 23907151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementation of next generation sequencing technology for somatic mutation detection in routine laboratory practice.
    Giardina T; Robinson C; Grieu-Iacopetta F; Millward M; Iacopetta B; Spagnolo D; Amanuel B
    Pathology; 2018 Jun; 50(4):389-401. PubMed ID: 29752127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Factors Affecting the Success of Next-Generation Sequencing Testing in Solid Tumors.
    Goswami RS; Luthra R; Singh RR; Patel KP; Routbort MJ; Aldape KD; Yao H; Dang HD; Barkoh BA; Manekia J; Medeiros LJ; Roy-Chowdhuri S; Stewart J; Broaddus RR; Chen H
    Am J Clin Pathol; 2016 Feb; 145(2):222-37. PubMed ID: 27124905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center's experiences.
    Cho M; Ahn S; Hong M; Bang H; Van Vrancken M; Kim S; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK; Sun JM; Lee SH; Ahn MJ; Park K; Kim DH; Lee S; Park W; Kim KM
    Oncotarget; 2017 Jun; 8(26):42478-42486. PubMed ID: 28477007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical mutational profiling of bone metastases of lung and colon carcinoma and malignant melanoma using next-generation sequencing.
    Zheng G; Lin MT; Lokhandwala PM; Beierl K; Netto GJ; Gocke CD; Eshleman JR; McCarthy E; Illei PB
    Cancer Cytopathol; 2016 Oct; 124(10):744-753. PubMed ID: 27286239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors.
    Luthra R; Patel KP; Routbort MJ; Broaddus RR; Yau J; Simien C; Chen W; Hatfield DZ; Medeiros LJ; Singh RR
    J Mol Diagn; 2017 Mar; 19(2):255-264. PubMed ID: 28017569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Feasibility of amplicon-based targeted next-generation sequencing of colorectal cancer in endoscopic biopsies].
    Wang YJ; Jiang RR; Liu HJ; Zhang B; Ye F; Bu H
    Zhonghua Bing Li Xue Za Zhi; 2018 Jul; 47(7):499-504. PubMed ID: 29996313
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes.
    Singh RR; Patel KP; Routbort MJ; Reddy NG; Barkoh BA; Handal B; Kanagal-Shamanna R; Greaves WO; Medeiros LJ; Aldape KD; Luthra R
    J Mol Diagn; 2013 Sep; 15(5):607-22. PubMed ID: 23810757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvaging the supernatant: next generation cytopathology for solid tumor mutation profiling.
    Roy-Chowdhuri S; Mehrotra M; Bolivar AM; Kanagal-Shamanna R; Barkoh BA; Hannigan B; Zalles S; Ye W; Duose D; Broaddus R; Staerkel G; Wistuba I; Medeiros LJ; Luthra R
    Mod Pathol; 2018 Jul; 31(7):1036-1045. PubMed ID: 29463880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.